Guideline for the prophylactic use of Rh D immunoglobulin in pregnancy care

Published by National Blood Authority on Mar 6, 2024

Disclaimer

Copyright and disclaimer 

© National Blood Authority, 2024. 

With the exception of any logos and registered trademarks, and where otherwise noted, all material presented in this document is provided under a Creative Commons Attribution-NonCommercial- ShareAlike 4.0 Australia (https://creativecommons.org/licenses/by-nc-sa/4.0/) licence. 

You are free to copy, communicate and adapt the work for non-commercial purposes, as long as you attribute the authors and distribute any derivative work (i.e. new work based on this work) only under this licence. 

If you adapt this work in any way or include it in a collection, and publish, distribute or otherwise disseminate that adaptation or collection to the public, it should be attributed in the following way: 

This work is based on/includes the National Blood Authority’s Guideline for the prophylactic use of Rh D immunoglobulin in pregnancy care, which is licensed under the Creative Commons Attribution- NonCommercial-ShareAlike 4.0 Australia licence. 

Where this work is not modified or changed, it should be attributed in the following way: 

© National Blood Authority, 2024. 

 

ISBN 978-0-6453281-2-7 (electronic copy) 

Sponsors

Contact

Abstract

v1.0:  06/03/2024

Please note this guideline is maintained electronically on MAGICapp. Any downloaded or printed version is only current as at the day of download/printing.

To keep up to date with the latest changes to this guideline click on subscribe at https://app.magicapp.org/#/guideline/n3QGej

Language

en-au

PICOS

PICO 1.1

Population
Rh D negative pregnant women with no preformed anti-D
Intervention
Universal routine antenatal Rh D immunoprophylaxis (one or two doses)
Comparator
no universal routine antenatal Rh D immunoprophylaxis
Outcomes

PICO 1.2

Population
Rh D negative pregnant women with no preformed anti-D
Intervention
Universal routine antenatal Rh D immunoprophylaxis (one or two doses)
Comparator
no universal routine antenatal Rh D immunoprophylaxis
Outcomes

PICO 1.3

Population
Rh D negative pregnant women with no preformed anti-D
Intervention
Universal routine antenatal Rh D immunoprophylaxis (one dose)
Comparator
Universal routine antenatal Rh D immunoprophylaxis (two doses)
Outcomes

PICO 2.1

Population
Rh D negative pregnant women with no preformed anti-D with a first 12 weeks of pregnancy sensitising event
Intervention
Routine sensitising event immunoprophylaxis
Comparator
Placebo or no sensitising event immunoprophylaxis
Outcomes

PICO 3.1

Population
Rh D negative pregnant women with no preformed anti-D
Intervention
Targeted antenatal Rh D Immunoprophylaxis (based on NIPT)
Comparator
Universal antenatal Rh D immunoprophylaxis
Outcomes

PICO 3.2

Population
Rh D negative pregnant women with no preformed anti-D (for routine or sensitising event immunoprophylaxis)
Intervention
NIP screening for fetal Rh D status
Comparator
Postnatal cord blood testing (or other neonatal sample) for fetal Rh D status or other noninvasive prenatal test for fetal Rh D status
Outcomes

PICO 4.1

Population
Rh D negative pregnant women with increased BMI and no preformed anti-D
Intervention
Increased dose of RAADP
Comparator
Not applicable
Outcomes